71 related articles for article (PubMed ID: 35528950)
1. Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine.
Rangsrisaeneepitak V; Porntharukchareon T; Dechates B; Sirisreetreerux S; Tawinprai K
Diabetol Int; 2022 Oct; 13(4):637-643. PubMed ID: 35528950
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.
Sirisreetreerux S; Porntharukchareon T; Dechates B; Rangsrisaeneepitak V; Therawit P; Worawitchawong S; Sornsamdang G; Soonklang K; Tawinprai K
Sci Rep; 2023 Jul; 13(1):11798. PubMed ID: 37479776
[TBL] [Abstract][Full Text] [Related]
3. Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study.
Mishra SK; Pradhan SK; Pati S; Sahu S; Nanda RK
Cureus; 2021 Nov; 13(11):e19879. PubMed ID: 34976499
[TBL] [Abstract][Full Text] [Related]
4. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Dechates B; Monprach H; Sornsamdang G; Wittayasak K; Soonklang K; Mahanonda N
Hum Vaccin Immunother; 2022 Dec; 18(1):2035573. PubMed ID: 35240945
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.
Asano M; Okada H; Itoh Y; Hirata H; Ishikawa K; Yoshida E; Matsui A; Kelly EJ; Shoemaker K; Olsson U; Vekemans J
Int J Infect Dis; 2022 Jan; 114():165-174. PubMed ID: 34688944
[TBL] [Abstract][Full Text] [Related]
6. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
Kulkarni PS; Padmapriyadarsini C; Vekemans J; Bavdekar A; Gupta M; Kulkarni P; Garg BS; Gogtay NJ; Tambe M; Lalwani S; Singh K; Munshi R; Meshram S; Selvavinayagam TS; Pandey K; Bhimarasetty DM; Ramakrishnan SR; Bhamare C; Dharmadhikari A; Vadakkedath R; Bonhomme CJ; Thakar M; Kurle SN; Kelly EJ; Gautam M; Gupta N; Panda S; Bhargava B; Shaligram U; Kapse D; Gunale B;
EClinicalMedicine; 2021 Dec; 42():101218. PubMed ID: 34870133
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
8. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
9. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
10. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
11. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222.
Nantanee R; Jantarabenjakul W; Jaru-Ampornpan P; Sodsai P; Himananto O; Athipunjapong J; Sophonphan J; Nanthapisal S; Hirankarn N; Puthanakit T;
Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746522
[TBL] [Abstract][Full Text] [Related]
13. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.
Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies.
Thookhamme C; Navinpipat M; Sasakul A; Pattarakosol P; Lertchaisataporn K; Tawinprai K; Praditsuktavorn P
Clin Exp Vaccine Res; 2023 Apr; 12(2):107-115. PubMed ID: 37214149
[TBL] [Abstract][Full Text] [Related]
15. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
16. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease.
Mehta P; Paul A; Ahmed S; Cherian S; Panthak A; Benny J; Shenoy P
Clin Rheumatol; 2022 Nov; 41(11):3537-3542. PubMed ID: 35760938
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2.
Lee SW; Lee H; Lee SK; Moon JY; Moon S; Chung SJ; Yeo Y; Park TS; Won Park D; Kim TH; Sohn JW; Yoon HJ; Kim SH
Front Med (Lausanne); 2021; 8():738049. PubMed ID: 34660644
[No Abstract] [Full Text] [Related]
19. Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production.
Müller M; Volzke J; Subin B; Müller S; Sombetzki M; Reisinger EC; Müller-Hilke B
BMC Med; 2022 Jan; 20(1):29. PubMed ID: 35042529
[TBL] [Abstract][Full Text] [Related]
20. Humoral antibody response to the first dose of the ChAdOx1 nCoV-19 vaccine in Asian patients undergoing hemodialysis.
Tung KT; Peng YS; Hsu SP; Wu HY; Chiu YL; Yang JY; Pai MF; Shu KH; Pan SY; Lu HM; Lin WY; Liao CH; Chu FY; Tsai WC
Hemodial Int; 2022 Jul; 26(3):369-376. PubMed ID: 35411681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
